Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.
Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 1 molecules, respectively.
Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Colitis - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colitis - Overview
Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Colitis - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Apollo Endosurgery Inc
Bristol-Myers Squibb Co
Concenter BioPharma Silkim Ltd
Cosmo Pharmaceuticals NV
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
Genfit SA
Immuron Ltd
Ogeda SA
Pfizer Inc
RDD Pharma Ltd
Saniona AB
Sigmoid Pharma Ltd
Synovo GmbH
Vitality Biopharma Inc
Colitis - Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-6899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSY-0073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyloxalylglycine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit LTC4 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06425090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Colitis and Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPC-1022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
Jul 19, 2017: Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease
Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Colitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Colitis - Pipeline by Akebia Therapeutics Inc, H1 2018
Colitis - Pipeline by Apollo Endosurgery Inc, H1 2018
Colitis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2018
Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2018
Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2018
Colitis - Pipeline by EA Pharma Co Ltd, H1 2018
Colitis - Pipeline by Genfit SA, H1 2018
Colitis - Pipeline by Immuron Ltd, H1 2018
Colitis - Pipeline by Ogeda SA, H1 2018
Colitis - Pipeline by Pfizer Inc, H1 2018
Colitis - Pipeline by RDD Pharma Ltd, H1 2018
Colitis - Pipeline by Saniona AB, H1 2018
Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2018
Colitis - Pipeline by Synovo GmbH, H1 2018
Colitis - Pipeline by Vitality Biopharma Inc, H1 2018
Colitis - Dormant Projects, H1 2018
Colitis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Colitis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Colitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 110
According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period.
The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
Global Lansoprazole Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 102
The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the comp......
Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 88
According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period.
The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
Global Esomeprazole Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 89
The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the comp......
Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 02-Jan-2024 Price: US 3380 Onwards Pages: 126
Market Overview of Global Irritable Bowel Syndrome (IBS) market:
According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 28-Dec-2023 Price: US 3380 Onwards Pages: 109
Market Overview of Global Diarrhea Drug market:
According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
Published: 27-Dec-2023 Price: US 3350 Onwards Pages: 96
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 3280 Onwards Pages: 136
Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Dec-2023 Price: US 3380 Onwards Pages: 113
Market Overview of Global Pentasa (Ulcerative Colitis) market:
According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
